Navigating a Complex Case of in a Patient with Blue Rubber Bleb Nevus Syndrome.

Introduction: Blue rubber bleb nevus syndrome is a rare disorder of venous malformations, with around 200 cases reported. We present a case of infection in a patient with blue rubber bleb nevus syndrome.

Case Description: A 40-year-old female with blue rubber bleb nevus syndrome, asthma, and bronchiectasis came to the pulmonology clinic with shortness of breath and a cough. She was recently admitted for a bronchiectasis exacerbation but continued to have a worsening productive cough and fevers. The most recent CT scan of the chest showed interval stable right upper lobe fibrocavitary disease, demonstrating gradual progression over two years. She had occasional positive cultures for and one year previously, assumed to be a colonizer and not treated. Most recent hospital cultures were negative for bacteria and an acid-fast bacilli smear. She was sent to the emergency department for bronchiectasis exacerbation and returned to the clinic six weeks later with two sputum cultures growing . It was decided to treat as this was likely the cause of her cavitary lung lesion and frequent infections. Azithromycin, rifampin, and sulfamethoxazole/trimethoprim were initiated. Intravenous amikacin was added later on. She finally had a right partial lung resection done after one year at an outside hospital. She was on and off antibiotics for for approximately three years with negative repeat cultures for non-tuberculous mycobacteria.

Conclusion: Due to the high mortality of infections (which can be as high as 69%), treatment of at least twelve months is recommended. To our knowledge, this is the first reported case of in a patient with blue rubber bleb nevus syndrome.

Learning Points: The decision to initiate treatment for non-tuberculous mycobacterium infections is often challenging with prolonged treatment.Lifetime monitoring is required in patients with blue rubber bleb nevus syndrome, which can have pulmonary complications. has the highest mortality among non-tuberculous mycobacterium infections and requires at least 12 months of treatment.